Polaris Group (TPE:6550)

Market Cap	23.42B
Revenue (ttm)	70.83M
Net Income (ttm)	-3.01B
Shares Out	770.47M
EPS (ttm)	-3.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	696,102
Average Volume	1,050,083
Open	30.25
Previous Close	30.20
Day's Range	29.70 - 30.40
52-Week Range	26.35 - 52.00
Beta	0.16
RSI	47.35
Earnings Date	Mar 13, 2026

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6550

Financial Performance

In 2024, Polaris Group's revenue was 107.00 million, an increase of 1330.29% compared to the previous year's 7.48 million. Losses were -2.50 billion, 67.7% more than in 2023.